Abnormal HDL lipid and protein composition following pediatric cancer treatment: an associative study.
Adolescents
Apolipoproteins
Chemotherapeutic agents
Children
Cholesterol
Clinical studies
Dyslipidemias
High density lipoprotein
Lipoproteins
Obesity
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
10 Jun 2023
10 Jun 2023
Historique:
received:
20
02
2023
accepted:
24
04
2023
medline:
12
6
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Long-term childhood cancer survivors (CCS) are at high risk of having dyslipidemia including low high density lipoprotein cholesterol (HDL-C). However, little is known about the prevalence of low HDL-C and the impact of therapy exposure on HDL composition early after treatment is terminated. This associative study included 50 children and adolescents who had completed their cancer treatments (< 4 years). Clinical characteristics (demographic, diagnosis, treatment, anthropometric parameters), fasting plasma lipids, apoliporoteins (Apo) A-I and composition of HDL fractions (HDL2 and HDL3) were assessed. Data were stratified according to the presence of dyslipidemia and median doses of therapeutic agents and compared using Fisher exact or Mann-Whitney tests. Univariate binary logistic regression analyses were carried out to evaluate the associations between the clinical and biochemical characteristics and having low HDL-C. Composition of HDL2 and HDL3 particles was assessed in a sub-group of 15 patients and compared to 15 age- and sex-matched healthy controls using Wilcoxon paired test. Of the 50 pediatric cancer patients included in this study (mean age: 11.30 ± 0.72 y; mean time since end of treatment: 1.47 ± 0.12 y; male: 38%), 8 had low HDL-C (16%), all of which were adolescent at diagnosis. Higher doses of doxorubicin were associated with lower HDL-C and Apo A-I levels. In hypertriglyceridemic patients and compared to normolipidemics, triglycerides (TG) content was greater in HDL2 and HDL3 fractions whereas esterified cholesterol (EC) content was lower in HDL2. Enrich TG content of HDL3 and lower EC of HDL2 was found in patients exposed to ≥ 90 mg/m Overall, we found abnormalities in HDL-C and Apo A-I levels and in HDL composition early after pediatric cancer treatment that are influenced by age, overweight or obesity status and exposure to doxorubicin.
Sections du résumé
BACKGROUND
BACKGROUND
Long-term childhood cancer survivors (CCS) are at high risk of having dyslipidemia including low high density lipoprotein cholesterol (HDL-C). However, little is known about the prevalence of low HDL-C and the impact of therapy exposure on HDL composition early after treatment is terminated.
METHODS
METHODS
This associative study included 50 children and adolescents who had completed their cancer treatments (< 4 years). Clinical characteristics (demographic, diagnosis, treatment, anthropometric parameters), fasting plasma lipids, apoliporoteins (Apo) A-I and composition of HDL fractions (HDL2 and HDL3) were assessed. Data were stratified according to the presence of dyslipidemia and median doses of therapeutic agents and compared using Fisher exact or Mann-Whitney tests. Univariate binary logistic regression analyses were carried out to evaluate the associations between the clinical and biochemical characteristics and having low HDL-C. Composition of HDL2 and HDL3 particles was assessed in a sub-group of 15 patients and compared to 15 age- and sex-matched healthy controls using Wilcoxon paired test.
RESULTS
RESULTS
Of the 50 pediatric cancer patients included in this study (mean age: 11.30 ± 0.72 y; mean time since end of treatment: 1.47 ± 0.12 y; male: 38%), 8 had low HDL-C (16%), all of which were adolescent at diagnosis. Higher doses of doxorubicin were associated with lower HDL-C and Apo A-I levels. In hypertriglyceridemic patients and compared to normolipidemics, triglycerides (TG) content was greater in HDL2 and HDL3 fractions whereas esterified cholesterol (EC) content was lower in HDL2. Enrich TG content of HDL3 and lower EC of HDL2 was found in patients exposed to ≥ 90 mg/m
CONCLUSIONS
CONCLUSIONS
Overall, we found abnormalities in HDL-C and Apo A-I levels and in HDL composition early after pediatric cancer treatment that are influenced by age, overweight or obesity status and exposure to doxorubicin.
Identifiants
pubmed: 37301877
doi: 10.1186/s12944-023-01822-2
pii: 10.1186/s12944-023-01822-2
pmc: PMC10257312
doi:
Substances chimiques
Lipoproteins, HDL
0
Apolipoprotein A-I
0
Cholesterol
97C5T2UQ7J
Triglycerides
0
Cholesterol, HDL
0
Cholesterol Esters
0
Doxorubicin
80168379AG
Lipoproteins, HDL3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Informations de copyright
© 2023. The Author(s).
Références
J Pediatr Hematol Oncol. 2010 Jul;32(5):383-9
pubmed: 20485196
Diabetol Metab Syndr. 2022 Jan 24;14(1):16
pubmed: 35073984
J Lipid Res. 2015 Sep;56(9):1727-37
pubmed: 26117661
Adv Clin Chem. 2014;65:1-41
pubmed: 25233609
PLoS One. 2016 Jun 30;11(6):e0158225
pubmed: 27362350
Curr Opin Lipidol. 2010 Aug;21(4):312-8
pubmed: 20581677
Cancer. 2017 Nov 1;123(21):4207-4214
pubmed: 28654149
J Lipid Res. 2017 May;58(5):982-993
pubmed: 28274961
Lancet Oncol. 2014 Jul;15(8):841-51
pubmed: 24954778
J Intern Med. 2004 Feb;255(2):188-205
pubmed: 14746556
J Natl Cancer Inst. 2020 Mar 1;112(3):256-265
pubmed: 31161223
Pediatr Blood Cancer. 2008 Feb;50(2):341-6
pubmed: 17918262
Nutr Cancer. 2022;74(9):3236-3252
pubmed: 35533005
Int J Mol Sci. 2019 Jun 27;20(13):
pubmed: 31252694
Sci Rep. 2019 Mar 12;9(1):4268
pubmed: 30862935
J Lipid Res. 1989 Aug;30(8):1197-209
pubmed: 2769073
Sci Rep. 2017 Dec 15;7(1):17684
pubmed: 29247169
BMC Pediatr. 2018 Sep 28;18(1):314
pubmed: 30266080
J Clin Oncol. 2013 Oct 10;31(29):3673-80
pubmed: 24002505
JAMA. 2016 Aug 9;316(6):645-55
pubmed: 27532919
Circ Res. 2013 Dec 6;113(12):1345-55
pubmed: 24055733
Pediatr Blood Cancer. 2013 Aug;60(8):1287-91
pubmed: 23444342
Pediatr Blood Cancer. 2012 Jan;58(1):31-6
pubmed: 21254377
Diabetes. 2001 Nov;50(11):2444-50
pubmed: 11679420
J Lipid Res. 1994 Dec;35(12):2170-7
pubmed: 7897315
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):190-7
pubmed: 25696854
Int J Mol Sci. 2022 Aug 03;23(15):
pubmed: 35955766
Cancer Res. 1989 Nov 1;49(21):5829-36
pubmed: 2790794
Korean J Pediatr. 2011 Jun;54(6):253-9
pubmed: 21949520
Curr Opin Lipidol. 2000 Apr;11(2):133-40
pubmed: 10787174
Cancers (Basel). 2021 Jul 19;13(14):
pubmed: 34298827
J Nutr. 2006 Apr;136(4):877-81
pubmed: 16549444
J Lipid Res. 2013 Nov;54(11):2950-63
pubmed: 23543772
Pediatrics. 2011 Dec;128 Suppl 5:S213-56
pubmed: 22084329
Nutrients. 2013 Feb 07;5(2):498-508
pubmed: 23434905
J Lipid Res. 1988 Feb;29(2):215-26
pubmed: 3130454
J Investig Med. 2019 Feb;67(2):295-302
pubmed: 30530528
Arch Intern Med. 2009 Aug 10;169(15):1381-8
pubmed: 19667301
J Pediatr. 2016 Mar;170:199-205
pubmed: 26706233
PLoS One. 2012;7(12):e52237
pubmed: 23251703
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):170-81
pubmed: 20056636
Eur Heart J. 2018 May 1;39(17):1555-1562
pubmed: 29534171
J Pediatr Hematol Oncol. 2004 May;26(5):289-93
pubmed: 15111780
Cardiovasc Diabetol. 2017 Oct 12;16(1):132
pubmed: 29025405
Biochim Biophys Acta. 2009 Dec;1791(12):1125-32
pubmed: 19635584
Lipids Health Dis. 2017 Feb 8;16(1):36
pubmed: 28179022
Biochemistry. 2008 Nov 4;47(44):11393-7
pubmed: 18839964
BMC Public Health. 2019 Dec 3;19(1):1627
pubmed: 31796007
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Int J Obes (Lond). 2006 Apr;30(4):590-4
pubmed: 16570087
J Clin Oncol. 2003 Apr 1;21(7):1359-65
pubmed: 12663727
BMC Pediatr. 2014 Feb 03;14:32
pubmed: 24490896
Transl Res. 2016 Jan;167(1):257-80
pubmed: 26207884
PLoS One. 2020 Apr 6;15(4):e0231209
pubmed: 32251440
Cancer. 2018 Nov 1;124(21):4248-4259
pubmed: 30358906
Can J Diet Pract Res. 2010 Spring;71(1):e1-3
pubmed: 21815309
N Engl J Med. 2015 Oct;373(14):1307-17
pubmed: 26422721
Blood. 2008 Jun 15;111(12):5515-23
pubmed: 18334672
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
Health Promot Chronic Dis Prev Can. 2016 Feb;36(2):32-40
pubmed: 26878492
Support Care Cancer. 2020 Jun;28(6):2627-2636
pubmed: 31620924
Front Pharmacol. 2015 Oct 16;6:222
pubmed: 26528181
Blood. 2012 Nov 29;120(23):4505-12
pubmed: 23034279
BMC Cancer. 2017 Feb 13;17(1):125
pubmed: 28193268
J Biol Chem. 1959 Mar;234(3):466-8
pubmed: 13641241
Lipids Health Dis. 2020 Mar 16;19(1):47
pubmed: 32178670
Eur Heart J. 2009 Sep;30(17):2137-46
pubmed: 19520708
Clin Transplant. 2017 Mar;31(3):
pubmed: 28039914
Cancer. 1998 Jul 15;83(2):379-84
pubmed: 9669823
N Engl J Med. 1995 Jun 29;332(26):1738-43
pubmed: 7760889
Neoplasma. 2019 Jul 12;66(6):978-987
pubmed: 31305124
Cardiovasc Res. 2014 Aug 1;103(3):362-71
pubmed: 24891399
FEBS Lett. 2015 Sep 14;589(19 Pt A):2627-39
pubmed: 25749369
Future Cardiol. 2012 Jul;8(4):647-70
pubmed: 22871201
Br J Haematol. 2014 May;165(3):364-74
pubmed: 24467690
ESMO Open. 2017 Dec 18;2(5):e000250
pubmed: 29326844
PLoS One. 2016 Jan 25;11(1):e0148049
pubmed: 26807857